Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study
High-flow nasal therapy (HFNT) provides several pathophysiological benefits in chronic respiratory disorders. We aimed to evaluate the effectiveness of long-term HFNT in patients with bronchiectasis (BE). Methods: This is a retrospective bicentric case-control study of outpatients with BE on optimiz...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/24/7323 |
| _version_ | 1797457045641756672 |
|---|---|
| author | Claudia Crimi Santi Nolasco Raffaele Campisi Mattia Nigro Pietro Impellizzeri Andrea Cortegiani Alberto Noto Andrea Gramegna Carlo Vancheri Francesco Blasi Nunzio Crimi Stefano Aliberti Annalisa Carlucci |
| author_facet | Claudia Crimi Santi Nolasco Raffaele Campisi Mattia Nigro Pietro Impellizzeri Andrea Cortegiani Alberto Noto Andrea Gramegna Carlo Vancheri Francesco Blasi Nunzio Crimi Stefano Aliberti Annalisa Carlucci |
| author_sort | Claudia Crimi |
| collection | DOAJ |
| description | High-flow nasal therapy (HFNT) provides several pathophysiological benefits in chronic respiratory disorders. We aimed to evaluate the effectiveness of long-term HFNT in patients with bronchiectasis (BE). Methods: This is a retrospective bicentric case-control study of outpatients with BE on optimized medical treatment with a severe exacerbation requiring hospitalization in the previous year. Patients on long-term home HFNT (cases) and patients on optimized medical treatment alone (controls) were matched by age, sex, bronchiectasis severity index, and exacerbations in the previous year. Data on BE exacerbations, hospitalizations/year, mucus features, respiratory symptoms, and pulmonary function were collected. The primary outcome was the change from baseline in the exacerbation rates at 12 months between groups. Results: 20 patients in the HFNT group and 20 controls were included. A significant reduction in exacerbations [−1.9 (−2.8 to −0.9), <i>p</i> = 0.0005] and hospitalizations [−0.7 (−1.1 to −0.3), <i>p</i> = 0.0006] was found in the HFNT group vs controls. A slight improvement in pulmonary function [FEV<sub>1</sub>% +6,1% (+1% to +11.3%) (<i>p</i> = 0.0219), FVC% +4.6% (+0.8% to +8.3%) (<i>p</i> = 0.0188) and FEF<sub>25–75</sub>% +13.4 (+11 to +15.9) (<i>p</i> = 0.0189) was also found in the HFNT group compared to controls. Conclusions: In this preliminary study, long-term domiciliary HFNT improved the clinical course of patients with BE. |
| first_indexed | 2024-03-09T16:16:33Z |
| format | Article |
| id | doaj.art-20cde2b5af0d4ca68940807b00cf8cc6 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T16:16:33Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-20cde2b5af0d4ca68940807b00cf8cc62023-11-24T15:43:35ZengMDPI AGJournal of Clinical Medicine2077-03832022-12-011124732310.3390/jcm11247323Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control StudyClaudia Crimi0Santi Nolasco1Raffaele Campisi2Mattia Nigro3Pietro Impellizzeri4Andrea Cortegiani5Alberto Noto6Andrea Gramegna7Carlo Vancheri8Francesco Blasi9Nunzio Crimi10Stefano Aliberti11Annalisa Carlucci12Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, ItalyDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, ItalyRespiratory Medicine Unit, Policlinico “G. Rodolico-San Marco” University Hospital, 95123 Catania, ItalyDepartment of Biomedical Sciences, Humanitas University, 20072 Milan, ItalyDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, ItalyDepartment of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, 90127 Palermo, ItalyDepartment of Human Pathology of the Adult and Evolutive Age “Gaetano Barresi”, Division of Anesthesia and Intensive Care, University of Messina, Policlinico “G. Martino”, 98125 Messina, ItalyDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, 20122 Milano, ItalyDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, ItalyDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, 20122 Milano, ItalyRespiratory Medicine Unit, Policlinico “G. Rodolico-San Marco” University Hospital, 95123 Catania, ItalyDepartment of Biomedical Sciences, Humanitas University, 20072 Milan, ItalyDepartment of Medicine and Surgery, Università degli Studi dell’Insubria, 21100 Varese, ItalyHigh-flow nasal therapy (HFNT) provides several pathophysiological benefits in chronic respiratory disorders. We aimed to evaluate the effectiveness of long-term HFNT in patients with bronchiectasis (BE). Methods: This is a retrospective bicentric case-control study of outpatients with BE on optimized medical treatment with a severe exacerbation requiring hospitalization in the previous year. Patients on long-term home HFNT (cases) and patients on optimized medical treatment alone (controls) were matched by age, sex, bronchiectasis severity index, and exacerbations in the previous year. Data on BE exacerbations, hospitalizations/year, mucus features, respiratory symptoms, and pulmonary function were collected. The primary outcome was the change from baseline in the exacerbation rates at 12 months between groups. Results: 20 patients in the HFNT group and 20 controls were included. A significant reduction in exacerbations [−1.9 (−2.8 to −0.9), <i>p</i> = 0.0005] and hospitalizations [−0.7 (−1.1 to −0.3), <i>p</i> = 0.0006] was found in the HFNT group vs controls. A slight improvement in pulmonary function [FEV<sub>1</sub>% +6,1% (+1% to +11.3%) (<i>p</i> = 0.0219), FVC% +4.6% (+0.8% to +8.3%) (<i>p</i> = 0.0188) and FEF<sub>25–75</sub>% +13.4 (+11 to +15.9) (<i>p</i> = 0.0189) was also found in the HFNT group compared to controls. Conclusions: In this preliminary study, long-term domiciliary HFNT improved the clinical course of patients with BE.https://www.mdpi.com/2077-0383/11/24/7323high-flow nasal cannulahigh-flow nasal therapybronchiectasismucusexacerbationhospitalization |
| spellingShingle | Claudia Crimi Santi Nolasco Raffaele Campisi Mattia Nigro Pietro Impellizzeri Andrea Cortegiani Alberto Noto Andrea Gramegna Carlo Vancheri Francesco Blasi Nunzio Crimi Stefano Aliberti Annalisa Carlucci Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study Journal of Clinical Medicine high-flow nasal cannula high-flow nasal therapy bronchiectasis mucus exacerbation hospitalization |
| title | Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study |
| title_full | Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study |
| title_fullStr | Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study |
| title_full_unstemmed | Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study |
| title_short | Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study |
| title_sort | long term domiciliary high flow nasal therapy in patients with bronchiectasis a preliminary retrospective observational case control study |
| topic | high-flow nasal cannula high-flow nasal therapy bronchiectasis mucus exacerbation hospitalization |
| url | https://www.mdpi.com/2077-0383/11/24/7323 |
| work_keys_str_mv | AT claudiacrimi longtermdomiciliaryhighflownasaltherapyinpatientswithbronchiectasisapreliminaryretrospectiveobservationalcasecontrolstudy AT santinolasco longtermdomiciliaryhighflownasaltherapyinpatientswithbronchiectasisapreliminaryretrospectiveobservationalcasecontrolstudy AT raffaelecampisi longtermdomiciliaryhighflownasaltherapyinpatientswithbronchiectasisapreliminaryretrospectiveobservationalcasecontrolstudy AT mattianigro longtermdomiciliaryhighflownasaltherapyinpatientswithbronchiectasisapreliminaryretrospectiveobservationalcasecontrolstudy AT pietroimpellizzeri longtermdomiciliaryhighflownasaltherapyinpatientswithbronchiectasisapreliminaryretrospectiveobservationalcasecontrolstudy AT andreacortegiani longtermdomiciliaryhighflownasaltherapyinpatientswithbronchiectasisapreliminaryretrospectiveobservationalcasecontrolstudy AT albertonoto longtermdomiciliaryhighflownasaltherapyinpatientswithbronchiectasisapreliminaryretrospectiveobservationalcasecontrolstudy AT andreagramegna longtermdomiciliaryhighflownasaltherapyinpatientswithbronchiectasisapreliminaryretrospectiveobservationalcasecontrolstudy AT carlovancheri longtermdomiciliaryhighflownasaltherapyinpatientswithbronchiectasisapreliminaryretrospectiveobservationalcasecontrolstudy AT francescoblasi longtermdomiciliaryhighflownasaltherapyinpatientswithbronchiectasisapreliminaryretrospectiveobservationalcasecontrolstudy AT nunziocrimi longtermdomiciliaryhighflownasaltherapyinpatientswithbronchiectasisapreliminaryretrospectiveobservationalcasecontrolstudy AT stefanoaliberti longtermdomiciliaryhighflownasaltherapyinpatientswithbronchiectasisapreliminaryretrospectiveobservationalcasecontrolstudy AT annalisacarlucci longtermdomiciliaryhighflownasaltherapyinpatientswithbronchiectasisapreliminaryretrospectiveobservationalcasecontrolstudy |